New cocktail of drugs takes on rare brain cancer

NCT ID NCT07350850

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental combo or standard therapy. The main goal is to see if the combo leads to more complete remissions. Researchers will also track side effects and survival for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pirtobrutinib, Sintilimab, Rituximab, and Methotrexate
What this could lead to: If successful, this combination could offer a more effective first-line treatment for primary CNS lymphoma, potentially improving response rates and survival.
What could go wrong: This is a phase 2 trial with only 77 participants, so results are preliminary. The combination may cause more side effects or not outperform standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCNSL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCNSL PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

China-Japan Union Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130033, China
Shanxi Provincial People's Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 030012, China
The First Affiliated Hospital of Fujian Medical University
RECRUITING

Xiamen, Fujian, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.